ARTICLE | Clinical News
Xeljanz: Phase III data
July 25, 2016 7:00 AM UTC
Top-line data from the double-blind, international Phase III OPAL Beyond trial in 395 patients with active psoriatic arthritis who had an inadequate response to >=1 tumor necrosis factor (TNF) inhibi...